Which recent advances have most changed triple-negative breast cancer treatment?
Three notable advances in recent triple-negative breast cancer (TNBC) care are:
1) Immunotherapy added to chemotherapy (early and metastatic settings)
- For patients whose tumors express PD-L1, adding pembrolizumab to standard chemotherapy has improved outcomes in both advanced and certain earlier-stage settings. This approach is used alongside chemo rather than replacing it, reflecting how TNBC often responds better when immune activation is combined with cytotoxic therapy.
2) Antibody-drug conjugates targeting specific tumor markers
- Trastuzumab deruxtecan is used for HER2-low metastatic breast cancer, which includes some TNBC cases where HER2 is low rather than fully positive. It represents a broader shift toward precision targeting using antibody-linked chemotherapy delivery.
3) New targeted options for metastatic disease based on tumor genetics
- For patients with germline BRCA mutations, therapies such as PARP inhibitors have expanded the targeted treatment landscape in metastatic TNBC, aiming to exploit defective DNA repair pathways. This has helped move some care decisions toward biomarker-driven regimens rather than chemotherapy alone.
What does “recent” usually mean in TNBC care?
In practice, “recent” usually refers to advances that have entered routine care over the past several years through major clinical trials and guideline updates, particularly around immunotherapy combinations, antibody-drug conjugates, and PARP inhibitor use in biomarker-defined patients.
Why do biomarkers matter so much in TNBC now?
TNBC is defined by the absence of ER, PR, and HER2 overexpression, but it still splits into biologically different groups. Biomarkers like PD-L1 and BRCA status help identify who benefits most from immunotherapy or targeted DNA-damage–pathway therapies, while marker status such as HER2-low can open eligibility to antibody-drug conjugates even when classic HER2-positive criteria are not met.
If a patient doesn’t have PD-L1 or BRCA mutations, what options remain?
Even without those markers, many patients still receive standard chemotherapy, and other treatment paths depend on disease stage and prior therapies. Current research continues to expand options beyond PD-L1 and BRCA, including additional antibody-drug conjugates and combination strategies.
Sources
I can name the three advances more precisely (including the exact trial/guideline context) if you share whether you mean recent advances in early-stage, metastatic, or both, and whether you want only FDA-approved changes.